Since its creation, the Foundation has been committed to engaging the community and supporting innovative and sustainable projects in the surgical field of lung transplantation, oesophageal diseases and thoracic oncology.

The ultimate goal is to ensure the growth and development of thoracic surgery in Quebec, providing excellence in clinical care, research and teaching, and promoting access to personalized and highly-specialized care, allowing us to better treat our patients and provide them with hope to overcome their disease.


Creation of “The Marcel and Rolande Gosselin Chair in Thoracic Surgical Oncology”

Endowment Fund of $3 million Tenured Title Holder: Dr. Moishe Liberman Partners : Marcel and Rolande Gosselin, The Thoracic Surgery Research Foundation of Montreal and the CHUM Foundation Our Mission :

  • To facilitate and improve the diagnosis and treatment of lung and oesophageal cancers
  • To support Dr. Moishe Liberman’s research laboratory
  • To develop an internationally-renowned reference center for thoracic endoscopic interventions;
  • To support the research efforts in the development of vaccines against tumours To sustain the development of the program within our Thoracic Surgery Division at the University of Montreal;
  • To offer grants for fellowship training of newly-recruited surgeons in thoracic oncology


Creation of the Alfonso Minicozzi and Family Chair in Thoracic Surgery and Lung Transplantation

Endowment Fund of $3 million Tenured Title Holder: Dr. Pasquale Ferraro Amount remaining to be funded: $1 million Partners : Alfonso Minicozzi and family, The thoracic Surgery Research Foundation of Montreal and the CHUM Foundation Our Mission :

  • To support lung transplant research activities
  • To ensure the growth and development of thoracic surgery in Quebec
  • To ensure succession in this domain, mainly through the offering of training grants for young, subspecialty surgeons
  • To promote the research and development, both clinical and fundamental, towards the preservation of the lungs and post- transplant pulmonary edema


Creation of CETOC

The CHUM Endoscopic Tracheobronchial and Oesophageal Center (C.E.T.O.C.)

Director: Dr. Moishe Liberman Investment: $1.5 million from The Thoracic Surgery Research Foundation of Montreal Our Mission :

  • Diagnosis, staging and treatment of diseases of the trachea, bronchi, lungs, oesophagus and mediastinum
  • Minimalize the need for invasive surgery


Acquisition of the Ex-Vivo Lung Transplant Perfusion Program

April 30th, 2014 – Dr. Pasquale Ferraro, Chief of the Division of Thoracic Surgery, Surgical Director of the Lung Transplant Program at the CHUM, and President of the Board of Directors of The Thoracic Surgery Research Foundation of Montreal, announced in a press conference, the acquisition of two Ex Vivo lung perfusion devices and, accompanied by his team, proceeded with the demonstration of its functionality. The first device was made available to the CHUM, and the second one is dedicated for research at the new CHUM Research Centre (CRCHUM).

This is a pioneering acquisition in the field of lung transplantation, with extraordinary potential. In fact, the CHUM became the second facility in North America to adopt this cutting-edge technology. This program is unique in Quebec and enables the CHUM to become the only hospital in Quebec where lung transplants are performed. 2015 was a record year at the Notre Dame Hospital, with a total of 57 lung transplants performed. The creation of this program by The Thoracic Research Foundation of Montreal has been made possible through the generous contributions of 4 major donors. To learn more, please click here  

Coming soon:

The Régis Morissette – Fransyl – Famille Morrissette Chair in Thoracic Surgery and Oesophageal Diseases

Endowment Fund of $3 million – on-going capitalization Tenured Title Holder: To be confirmed Partners : The Morissette family, Fransyl, The Thoracic Surgery Research Foundation of Montreal, the CHUM Foundation Our Mission:

  • Develop new approaches to assess and treat oesophageal diseases
  • Identify the causes that transform of benign oesophageal diseases to cancerous diseases
  • Initiate and maintain a registry for the monitoring of patients with Barrett’s oesophagus
  • Assess the social impact of a precancerous disesase prevention screeening of the oesophagus
  • Define an ideal therapeutic approach for patients with oesophageal cancer